Cyclobenzaprine HCl Tablets Rx
Generic Name and Formulations:
Cyclobenzaprine HCl 5mg, 7.5mg, 10mg; tabs.
Various generic manufacturers
Indications for Cyclobenzaprine HCl Tablets:
Relief of acute muscle spasm, as adjunct to rest and physical therapy.
≥15yrs: initially 5mg 3 times daily, may increase to 10mg 3 times daily; max 2–3 weeks. Elderly or mild hepatic impairment: initially 5mg and then titrate slowly upward.
<15yrs: not established.
Acute post-MI. Arrhythmias, heart block, other conduction disturbances. CHF. Hyperthyroidism. During or within 14 days of MAOIs.
Moderate-to-severe hepatic impairment: not recommended. Urinary retention. Glaucoma. Increased intraocular pressure. Elderly. Pregnancy (Cat.B). Nursing mothers.
Muscle relaxant (central).
See Contraindications. Hypertensive crisis with MAOIs. Increased risk of serotonin syndrome with other serotonergic drugs (eg, SSRIs, SNRIs, tricyclic antidepressants, tramadol, bupropion, meperidine, verapamil, or MAOIs); monitor closely. Potentiates anticholinergics, alcohol, other CNS depressants. May antagonize guanethidine, clonidine. Tramadol increases seizure risk.
Drowsiness, dry mouth, dizziness, fatigue, headache, GI upset, asthenia, irritability, nervousness, blurred vision, confusion, arrhythmias, tachycardia, hypotension.
Formerly known under the brand names Flexeril, Fexmid.
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness